☰

Alysa Walker, Ph.D. - Publications

Affiliations: 
2010 University of Washington, Seattle, Seattle, WA 
Area:
Pharmacy, Pharmacology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology. 116: 432-47. PMID 22273859 DOI: 10.1097/Aln.0B013E3182423478  0.638
2011 Walker AA, Leslie D, Isoherranen N. Pregnancy decreases rat CYP1A2 activity and expression Drug Metabolism and Disposition. 39: 4-7. PMID 20921303 DOI: 10.1124/Dmd.110.035766  0.498
2009 Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug and Alcohol Dependence. 101: 158-68. PMID 19232844 DOI: 10.1016/J.Drugalcdep.2008.12.009  0.576
2009 Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology. 110: 660-72. PMID 19225389 DOI: 10.1097/Aln.0B013E3181986A9A  0.619
2008 Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clinical Pharmacology and Therapeutics. 84: 506-12. PMID 19238656 DOI: 10.1038/Clpt.2008.102  0.574
2008 Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clinical Pharmacology and Therapeutics. 84: 497-505. PMID 19238655 DOI: 10.1038/Clpt.2008.104  0.571
2007 Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clinical Pharmacology and Therapeutics. 82: 410-26. PMID 17554244 DOI: 10.1038/Sj.Clpt.6100237  0.567
2005 Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. Journal of Clinical Pharmacology. 45: 1187-97. PMID 16172184 DOI: 10.1177/0091270005280077  0.538
2005 Kharasch ED, Walker A, Hoffer C, Sheffels P. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. Journal of Clinical Pharmacology. 45: 79-88. PMID 15601808 DOI: 10.1177/0091270004269705  0.482
2004 Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clinical Pharmacology and Therapeutics. 76: 452-66. PMID 15536460 DOI: 10.1016/J.Clpt.2004.07.006  0.624
2004 Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of intravenous and oral alfentanil miosis as a noninvasive probe for hepatic and first‐pass CYP3A activity Clinical Pharmacology & Therapeutics. 75: 81. DOI: 10.1016/J.Clpt.2003.11.310  0.592
2004 Kharasch ED, Walker A, Hoffer C, Sheffels P. Miosis following intravenous and oral alfentanil as a noninvasive probe for hepatic and first‐pass CYP3A activity Clinical Pharmacology & Therapeutics. 75: 81. DOI: 10.1016/J.Clpt.2003.11.309  0.59
2003 Kharasch ED, Hoffer C, Walker A, Sheffels P. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clinical Pharmacology and Therapeutics. 73: 199-208. PMID 12621385 DOI: 10.1067/Mcp.2003.30  0.597
2003 Kharasch E, Hoffer C, Walker A, Sheffels P. Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass CYP3A activity. Clinical Pharmacology & Therapeutics. 73: P17-P17. DOI: 10.1016/S0009-9236(03)90418-8  0.452
2003 Walker A, Hoffer CJ, Sheffels P, Kharasch E. Alfentanil and fexofenadine combination to probe intestinal CYP3A and P‐glycoprotein activities Clinical Pharmacology & Therapeutics. 73. DOI: 10.1016/S0009-9236(03)90417-6  0.464
Show low-probability matches.